Exondys 51
Total Payments
$6.1M
Transactions
2,185
Doctors
656
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $986,374 | 238 | 8 |
| 2023 | $813,082 | 239 | 47 |
| 2022 | $1.0M | 430 | 189 |
| 2021 | $564,221 | 200 | 23 |
| 2020 | $2.0M | 192 | 80 |
| 2019 | $710,687 | 886 | 404 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $5.3M | 833 | 86.6% |
| Consulting Fee | $430,253 | 95 | 7.0% |
| Grant | $198,784 | 11 | 3.3% |
| Travel and Lodging | $128,809 | 209 | 2.1% |
| Food and Beverage | $30,783 | 986 | 0.5% |
| Royalty or License | $25,545 | 1 | 0.4% |
| Space rental or facility fees (teaching hospital only) | $1,045 | 1 | 0.0% |
| Education | $713.22 | 48 | 0.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $336.00 | 1 | 0.0% |
Payments by Type
Research
$5.3M
833 transactions
General
$816,267
1,352 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| 4658-301 | Sarepta Therapeutics, Inc. | $2.2M | 0 |
| 4658-402 | Sarepta Therapeutics, Inc. | $1.7M | 1 |
| 4658-403 | Sarepta Therapeutics, Inc. | $1.3M | 0 |
| 4658?301-a1 | Sarepta Therapeutics, Inc. | $101,729 | 0 |
| 4658?301 | Sarepta Therapeutics, Inc. | $20,988 | 0 |
| 4658-301-a1 | Sarepta Therapeutics, Inc. | $11,434 | 0 |
| 4658-102 OLE | Sarepta Therapeutics, Inc. | $1,600 | 1 |
| 4658-102 | Sarepta Therapeutics, Inc. | $1,200 | 1 |
Top Doctors Receiving Payments for Exondys 51 — Page 4
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Pediatrics | New Orleans, LA | $158.08 | 9 |
| , M.D | Neurodevelopmental Disabilities | Sacramento, CA | $148.56 | 7 |
| , M.D | Internal Medicine | Honolulu, HI | $146.67 | 2 |
| , MD | Pediatrics | Detroit, MI | $146.26 | 1 |
| , M.D | Neurology | Brooklyn, NY | $133.27 | 1 |
| , D.O | Pediatrics | Gainesville, FL | $132.83 | 2 |
| , MD, PHD | Neurology | Boston, MA | $131.74 | 1 |
| , MD | Pediatrics | Miami, FL | $128.15 | 1 |
| , MD | Pediatrics | Rockland, DE | $128.15 | 1 |
| , M.D | Internal Medicine | Honolulu, HI | $124.98 | 1 |
| , M.D | Internal Medicine | Honolulu, HI | $124.97 | 1 |
| , MD | Neurology with Special Qualifications in Child Neurology | New Orleans, LA | $117.20 | 5 |
| , MD | Neurology with Special Qualifications in Child Neurology | New Orleans, LA | $107.75 | 5 |
| , MD | Neurodevelopmental Disabilities | Brownsville, TX | $105.56 | 5 |
| , MD | Physical Medicine & Rehabilitation | Boise, ID | $101.94 | 5 |
| , M.D | Neuromusculoskeletal Medicine & OMM | Alexandria, LA | $101.01 | 5 |
| , MD | Neurology with Special Qualifications in Child Neurology | Washington, DC | $99.96 | 4 |
| , MD | Neurology | Orange, CA | $79.95 | 4 |
| , M.D | Neurology with Special Qualifications in Child Neurology | Madera, CA | $77.96 | 4 |
| , D.C | Chiropractor | Irvine, CA | $77.81 | 1 |
| , M.D | Pediatrics | Long Beach, CA | $77.49 | 5 |
| , M.D., PH.D | Neurology with Special Qualifications in Child Neurology | Corpus Christi, TX | $76.92 | 2 |
| , MD | Neurology with Special Qualifications in Child Neurology | New Orleans, LA | $73.91 | 3 |
| , MD | Neurology with Special Qualifications in Child Neurology | Metairie, LA | $73.69 | 3 |
| , M.D | Neurology with Special Qualifications in Child Neurology | Loma Linda, CA | $72.46 | 4 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $6.1M
- Total Doctors 656
- Transactions 2,185
About Exondys 51
Exondys 51 is a drug associated with $6.1M in payments to 656 healthcare providers, recorded across 2,185 transactions in the CMS Open Payments database. The primary manufacturer is Sarepta Therapeutics, Inc..
Payment data is available from 2019 to 2024. In 2024, $986,374 was paid across 238 transactions to 8 doctors.
The most common payment nature for Exondys 51 is "Unspecified" ($5.3M, 86.6% of total).
Exondys 51 is associated with 8 research studies, including "4658-301" ($2.2M).